Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy

Biochemical and Biophysical Research Communications

Volumn 447, Issue 3, 2014, Pages 537-542

  Ning, Shoucheng ^a   Bednarski, Mark ^b   Oronsky, Bryan ^c   Scicinski, Jan ^c   Knox, Susan J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RadioRx Inc   (United States)

Author keywords

Blood flow; Cancer; Chemotherapy; Nitric oxide; Radiotherapy

Indexed keywords

2 (4 CARBOXYPHENYL) 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; ACETYLCYSTEINE; CISPLATIN; GLYCIDYL NITRATE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR BLOOD FLOW;

MUS;

BLOOD FLOW; CANCER; CHEMOTHERAPY; NITRIC OXIDE; RADIOTHERAPY;

ANIMALS; BENZOATES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPOXY COMPOUNDS; HT29 CELLS; HUMANS; IMIDAZOLES; MALE; MICE; MICE, INBRED C3H; NEOPLASMS; NITRATES; NITRIC OXIDE; NITRIC OXIDE DONORS; RADIATION-SENSITIZING AGENTS; REGIONAL BLOOD FLOW;

EID: 84900309282     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.032     Document Type: Article

References (31)

1. Fried L.E., Manaa M.R., Pageria P.F., Simpson R.L. Design and synthesis of energetic materials. Annu. Rev. Mater. Res. 2001, 31:291-321.
2. Ning S., Bednarski M., Oronsky B., Scicinski J., Saul G., Knox S.J. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012, 72:2600-2608.
3. Scicinski J., Oronsky B., Taylor M., Luo G., Musick T., Marini J., Adams C.M., Fitch W.L. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anti-cancer agent. Drug Metab. Dispos. 2012, 40:1810-1816.
4. Korotkikh N.I., Losev G.A., Lipnitskii V.F., Kalistratov S.G., Sokolova A.S., Shvaika O.P. Synthesis and antitumor activity of epoxy heterocyclic compounds. Pharm. Chem. J. 1993, 27:67-71.
5. Toshima K., Okuno Y., Matsumura S. Glycidol-carbohydrate hybrids: a new family of DNA alkylating agents. Bioorg. Med. Chem. Lett. 2003, 13:3281-3283.
6. Oronsky B.T., Knox S.J., Scicinski J. Is nitric oxide (NO) the last word in radiosensitization? a review. Transl. Oncol. 2012, 5:66-71.
7. Hirst D., Robson T. Targeting nitric oxide for cancer therapy. J. Pharm. Pharmacol. 2007, 59:3-13.
8. Lechner M., Lirk P., Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin. Cancer Biol. 2005, 15:277-289.
9. Szabo C., Ischiropoulos H., Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 2007, 6:662-680.
10. Sidorkina O., Espey M.G., Miranda K.M., Wink D.A., Laval J. Inhibition of poly(ADP-RIBOSE) polymerase (PARP) by nitric oxide and reactive nitrogen oxide species. Free Radic. Biol. Med. 2003, 35:1431-1438.
11. Mitchell J.B., Wink D.A., DeGraff W., Gamson J., Keefer L.K., Krishna M.C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 1993, 53:5845-5848.
12. Mitchell J.B., Cook J.A., Krishna M.C., DeGraff W., Gamson J., Fisher J., Christodoulou D., Wink D.A. Radiation sensitisation by nitric oxide releasing agents. Br. J. Cancer 1996, 27(Suppl.):S181-S184.
13. Mitchell J.B., DeGraff W., Kim S., Cook J.A., Gamson J., Christodoulou D., Feelisch M., Wink D.A. Redox generation of nitric oxide to radiosensitize hypoxic cells. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:795-798.
14. Janssens M.Y., Verovski V.N., Van den Berge D.L., Monsaert C., Storme G.A. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br. J. Cancer 1999, 79:1085-1089.
15. Griffin R.J., Macpeace C.M., Hur W.J., Song C.W. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:377-383.
16. De Ridder M., Verellen D., Verovski V., Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008, 19:164-169.
17. Matsumoto H., Hayashi S., Hatashita M., Ohnishi K., Shioura H., Ohtsubo T., Kitai R., Ohnishi T., Kano E. Induction of radioresistance by a nitric oxide-mediated bystander effect. Radiat. Res. 2001, 155:387-396.
18. Liebmann J., DeLuca A.M., Coffin D., Keefer L.K., Venzon D., Wink D.A., Mitchell J.B. In vivo radiation protection by nitric oxide modulation. Cancer Res. 1994, 54:3365-3368.
19. Son K.K., Hall K.J. Nitric oxide-mediated tumor cell killing of cisplatin-based interferon-gamma gene therapy in murine ovarian carcinoma. Cancer Gene Ther. 2000, 7:1324-1328.
20. Oshima T., Imada T., Nagashima Y., Cho H., Shiozawa M., Rino Y., Takanashi Y. Role of nitric oxide in human gastric cancer cells treated with 5 fluorouracil. Oncol. Rep. 2001, 8:847-849.
21. Konovalova N.P., Goncharova S.A., Volkova L.M., Rajewskaya T.A., Eremenko L.T., Korolev A.M. Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide 2003, 8:59-64.
22. Frederiksen L.J., Sullivan R., Maxwell L.R., Macdonald-Goodfellow S.K., Adams M.A., Bennett B.M., Siemens D.R., Graham C.H. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin. Cancer Res. 2007, 13:2199-2206.
23. Sullivan R., Graham C.H. Chemosensitization of cancer by nitric oxide. Curr. Pharm. Des. 2008, 14:1113-1123.
24. Weyerbrock A., Baumer B., Papazoglou A. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro. J. Neurosurg. 2009, 110:128-136.
25. Heaton J.P., Adams M.A., Graham C.H., Emerson L., Siemens R.D. Evidence for the use of low dose nitric oxide in the treatment of rising PSA associated with biochemical failure following radical prostatectomy. J. Urol. 2003, 169(Suppl. S):1082.
26. Squadrito G.L., Pryor W.A. Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic. Biol. Med. 1998, 4-5:392-403.
27. Casaril M., Corso F., Bassi A., Capra F., Gabrielli G.B., Stanzial A.M., Nicoli N., Corrocher R. Decreased activity of scavenger enzymes in human hepatocellular carcinoma, but not in liver metastases. Int. J. Clin. Lab. Res. 1994, 24:94-97.
28. Kashiwagi S., Tsukada K., Xu L., Miyazaki J., Kozin S.V., Tyrrell J.A., Sessa W.C., Gerweck L.E., Jain R.K., Fukumura D. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 2008, 14:255-257.
29. Ridnour L.A., Isenberg J.S., Espey M.G., Thomas D.D., Roberts D.D., Wink D.A. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc. Natl. Acad. Sci. 2005, 102:13147-13152.
30. Rudic R.D., Shesely E.G., Maeda N., Smithies O., Segal S.S., Sessa W.C. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Invest. 1998, 101:731-736.
31. Yasuda H., Yamaya M., Nakayama K., Sasaki T., Ebihara S., Kanda A., Asada M., Inoue D., Suzuki T., Okazaki T., Takahashi H., Yoshida M., Kaneta T., Ishizawa K., Yamanda S., Tomita N., Yamasaki M., Kikuchi A., Kubo H., Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. 2006, 24:688-694.